Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 25, 2025 07:00 ET | Source: Sobi, Inc.

Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)

Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in...
December 12, 2024 06:59 ET | Source: Sobi, Inc.

Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia

WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration...
November 06, 2023 13:07 ET | Source: Sobi, Inc.

Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia

Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
December 30, 2020 08:48 ET | Source: Research and Markets

Doptelet (Avatrombopag): A 2nd Generation, Once Daily, Orally Administered TPO Receptor Agonist Approved for the Treatment of Thrombocytopenia - Global Drug Insight and Market Forecast 2017-2030

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Doptelet (Avatrombopag) - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Doptelet (avatrombopag)...